INS and Hypoglycemia: Compared with participants treated with degludec, IDegLira‐treated participants had lower weight gain and reduced rates of hypoglycemia, which have been associated with insulins such as degludec,17 as well as lower rates of gastrointestinal adverse events (AEs), which occur frequently with GLP‐1RAs.18